Camac Fund, L.P.

Company overview. Camac Fund, L.P. is a Delaware limited partnership and activist hedge fund with its principal office at 350 Park Avenue, 13th Floor, New York, NY. It is the flagship of a small fund complex that also includes Camac Fund II, LP; Camac Partners, LLC (investment manager); and Camac Capital, LLC (general partner), all controlled by Eric Shahinian, who is also the group's public face in SEC filings. First Form D filings for the fund date to 2011. Camac Partners' Form ADV (CRD #173002, SEC #801-126104) reported roughly $153 million in assets under management across two pooled investment vehicles and two employees as of March 2023; no current, independently verified AUM or headcount is available.

Products / services. Camac is not an operating company. Its business is investing in securities — specifically, concentrated activist positions in small- and micro-cap issuers — and it generates returns through portfolio appreciation and, frequently, through governance campaigns. It does not manufacture, license, or sell products, and it holds no asserted patent portfolio. Public filings show positions or campaigns involving Forte Biosciences, TuSimple Holdings, Gold Reserve Ltd., Cedar Realty Trust, and other listed issuers.

Litigation posture. The tracked data show one case, Camac Fund, L.P. v. Chen, in the Delaware Court of Chancery, with Camac as plaintiff and no defendant-side appearances. That profile — a fund filing suit rather than being sued — is consistent with an investor bringing governance or books-and-records-type claims, not with a patent assertion entity. Notably, the single tracked matter is a Chancery corporate action, not a patent infringement suit, and it is not venue-clustered in the Eastern District of Texas. No patent holdings or licensing revenue were identified for Camac.

Context and limits. Camac's better-documented litigation history includes Chancery books-and-records and fiduciary-duty actions against Forte Biosciences (including Camac Fund, LP v. Paul A. Wagner, et al.) and a dismissed 2023 Texas action, Forte Biosciences v. Camac Fund, LP, et al. I could not independently verify the parties, subject matter, or status of Camac Fund, L.P. v. Chen from public sources, so no details of that matter are asserted here.